Trials / Completed
CompletedNCT05619926
Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without Inhibitor
A Multi-center, Open-label, Multiple-dose Design, Phase 2 Trial to Evaluate the Safety and Efficacy of STSP-0601 for Injection in Patients With Hemophilia Without Inhibitor
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd · Industry
- Sex
- Male
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the safety,efficacy,pharmacokinetics and pharmacodynamics of multiple-dose of STSP-0601 at two dose levels for the treatment of bleeding episodes in hemophilia A or B patients without inhibitor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | STSP-0601 for Injection | Intravenous Injection |
Timeline
- Start date
- 2023-01-09
- Primary completion
- 2023-08-25
- Completion
- 2023-08-25
- First posted
- 2022-11-17
- Last updated
- 2024-01-02
Locations
12 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05619926. Inclusion in this directory is not an endorsement.